Processa Pharmaceuticals Inc
$ 2.57
11.74%
07 Aug - close price
- Market Cap 8,614,600 USD
- Current Price $ 2.57
- High / Low $ 2.64 / 2.32
- Stock P/E N/A
- Book Value 0.95
- EPS -4.07
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.94 %
- ROE -4.65 %
- 52 Week High 14.25
- 52 Week Low 1.67
About
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
Analyst Target Price
$25.00
Quarterly Earnings
| Jun 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-20 | 2024-10-30 | 2024-08-13 | 2024-05-10 | 2024-03-29 | 2023-11-13 | 2023-08-10 | 2023-05-15 |
| Reported EPS | -6.25 | -1.75 | -0.25 | -7.5 | -0.74 | -25.75 | -25.25 | -27.75 | -1.7 | -40 | -50 | -0.18 |
| Estimated EPS | None | -2 | -0.23 | -19.25 | -0.92 | -25 | -24.5 | -29.5 | -1.6 | -50 | -75 | -0.28 |
| Surprise | 0 | 0.25 | -0.02 | 11.75 | 0.18 | -0.75 | -0.75 | 1.75 | -0.1 | 10 | 25 | 0.1 |
| Surprise Percentage | None% | 12.5% | -8.6957% | 61.039% | 19.5652% | -3% | -3.0612% | 5.9322% | -6.25% | 20% | 33.3333% | 35.7143% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCSA
2026-08-07 20:41:42
This article provides an earnings forecast for Processa Pharmaceuticals Inc (PCSA), noting that no earnings forecast score is currently available. It details the average price target from analysts, which is $1.00, suggesting a significant upside. The report also includes recent and expected EPS figures and a peer comparison based on analyst ratings.
2026-08-04 23:40:33
Processa Pharmaceuticals held its 2026 annual shareholder meeting on July 30, 2026. Shareholders approved an amended 2019 omnibus incentive plan, ratified Cherry Bekaert as the independent accounting firm for 2026, and approved a slate of six directors. This news brief was generated by AI using information from Processa Pharmaceuticals Inc.'s EDGAR filing.
2026-08-04 21:40:33
Processa Pharmaceuticals (NASDAQ: PCSA) announced that its shareholders approved an amendment to the company’s 2019 Omnibus Incentive Plan during its 2026 Annual Meeting. This amendment increases the number of shares available for issuance under the plan by 200,000. The proposal received significant shareholder support, with 579,877 votes in favor.
2026-08-04 19:40:33
Mintz advised the placement agents on a $200 million private placement, which was executed in conjunction with Processa Pharmaceuticals, Inc.'s acquisition of Vidya Therapeutics, Inc. Leerink Partners led the placement, with Evercore ISI, UBS Investment Bank, and Wells Fargo Securities acting as co-placement agents. The Mintz team involved experts in capital markets, regulatory affairs, and intellectual property.
2026-08-02 07:40:07
This article provides detailed earnings data for Processa Pharmaceuticals Inc (PCSA), including historical EPS and revenue, upcoming earnings dates, and analyst forecasts. It also explains what an earnings surprise means and how earnings reports can impact PCSA stock performance.
2026-08-01 18:41:42
Processa Pharmaceuticals (PCSA) announced an M&A deal involving the acquisition of Vidya, bringing a new CNS-penetrant BTK inhibitor (VT-7208) into its pipeline to target immune-mediated and neuroinflammatory diseases. The transaction is structured as a stock-for-stock exchange, coupled with a $200 million private placement that is expected to fund operations into the second half of 2029 and through multiple clinical milestones. Post-acquisition, new investors will hold the majority stake on a fully diluted basis, with a shareholder vote anticipated in Q4 2026 to convert Series A preferred stock to common stock.
